Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Invested Capital (2016 - 2025)

Altimmune (ALT) has disclosed Invested Capital for 16 consecutive years, with $200.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 50.4% to $200.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $200.6 million, a 50.4% increase, with the full-year FY2024 number at $123.5 million, down 36.37% from a year prior.
  • Invested Capital was $200.6 million for Q3 2025 at Altimmune, up from $176.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $246.4 million in Q1 2021 to a low of $123.5 million in Q4 2024.
  • A 5-year average of $182.0 million and a median of $185.3 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 488.2% in 2021, then crashed 36.37% in 2024.
  • Altimmune's Invested Capital stood at $205.2 million in 2021, then dropped by 9.71% to $185.3 million in 2022, then increased by 4.75% to $194.1 million in 2023, then plummeted by 36.37% to $123.5 million in 2024, then soared by 62.42% to $200.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Invested Capital are $200.6 million (Q3 2025), $176.4 million (Q2 2025), and $142.2 million (Q1 2025).